PLOD1 and hypogonadism: Of the three studies that did, Isaksson did take into account testosterone and LH levels and use of hormone replacement therapy to define hypogonadism and found that hypogonadal patients with and without androgen replacement therapy had 6%–9% lower hip BMD (p = 0.043 and p = 0.037, respectively).24